288
Views
12
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma

, , , , , , & show all
Pages 1341-1348 | Received 27 Jun 2016, Accepted 08 Sep 2016, Published online: 09 Oct 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Long Qian, Miaoming Yan, Wei Zhang, Daobin Zhou, Yan Zhang, Li Huo, Yaping Luo, Yingqiang Zhang & Shaoxuan Hu. (2020) Prognostic value of interim 18F-FDG PET/CT in T-cell lymphomas. Leukemia & Lymphoma 61:4, pages 927-933.
Read now

Articles from other publishers (11)

Woo Hee Choi, Eun Ji Han, Joo Hyun O, Eun Kyoung Choi, Joon-Il Choi, Gyeongsin Park, Byung-Ock Choi, Young-Woo Jeon, Gi-June Min & Seok-Goo Cho. (2023) Prognostic Value of FDG PET/CT in Patients with Nodal Peripheral T-Cell Lymphoma. Diagnostics 13:17, pages 2834.
Crossref
Lucia Zanoni, Davide Bezzi, Cristina Nanni, Andrea Paccagnella, Arianna Farina, Alessandro Broccoli, Beatrice Casadei, Pier Luigi Zinzani & Stefano Fanti. (2023) PET/CT in Non-Hodgkin Lymphoma: An Update. Seminars in Nuclear Medicine 53:3, pages 320-351.
Crossref
Merissa N. Zeman, Esma A. Akin, Reid W. Merryman & Heather A. Jacene. (2023) Interim FDG-PET/CT for Response Assessment of Lymphoma. Seminars in Nuclear Medicine 53:3, pages 371-388.
Crossref
Mostafa F. Mohammed Saleh, Ahmed Kotb, Ghada E. M. Abdallah, Ibrahim N. Muhsen, Riad El Fakih & Mahmoud Aljurf. (2021) Recent Advances in Diagnosis and Therapy of Angioimmunoblastic T Cell Lymphoma. Current Oncology 28:6, pages 5480-5498.
Crossref
Raphael Koch & Lorenz Truempe. 2021. The Peripheral T‐Cell Lymphomas. The Peripheral T‐Cell Lymphomas 269 286 .
Christine Schmitz, Jan Rekowski, Stefan P. Müller, Bernd Hertenstein, Christiane Franzius, Arnold Ganser, Frank M. Bengel, Frank Kroschinsky, Jörg Kotzerke, Paul La Rosée, Martin Freesmeyer, Heinz‐Gert Hoeffkes, Andreas Hertel, Dirk Behringer, Rolf Mesters, Matthias Weckesser, Stefan Mahlmann, Uwe Haberkorn, Uwe Martens, Gabriele Prange‐Krex, Winfried Brenner, Aristoteles Giagounidis, Regina Moeller, Volker Runde, Matthias Sandmann, Hubertus Hautzel, Stefan Wilop, Thomas Krohn, Heinz Dürk, Michael Heike, Ferras Alashkar, Marcus Brinkmann, Guido Trenn, Dietmar Wacker, Christiane Kreisel‐Büstgens, Helga Bernhard, Gerhard Heil, Rolf Larisch, Lars Kurch, Karl‐Heinz Jöckel, Dieter Hoelzer, Wolfram Klapper, Ronald Boellaard, Ulrich Dührsen & Andreas Hüttmann. (2020) Baseline and interim PET‐based outcome prediction in peripheral T‐cell lymphoma: A subgroup analysis of the PETAL trial. Hematological Oncology 38:3, pages 244-256.
Crossref
Da-Yong Huang, Yi-Fei Hu, Na Wei, Li Fu, Lin Wu, Jing Shen, Jing-Shi Wang & Zhao Wang. (2019) Innovative analysis of predictors for overall survival from systemic non-Hodgkin T cell lymphoma using quantile regression analysis. Chinese Medical Journal 132:3, pages 294-301.
Crossref
Shengming Deng, Bin Zhang, Yeye Zhou, Xin Xu, Jihui Li, Shibiao Sang & Wei Zhang. (2018) The Role of 18 F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie–Salmon Plus and Other Staging Systems . Contrast Media & Molecular Imaging 2018, pages 1-9.
Crossref
Jeong Won Lee & Sang Mi Lee. (2017) Radiomics in Oncological PET/CT: Clinical Applications. Nuclear Medicine and Molecular Imaging 52:3, pages 170-189.
Crossref
Marius E. Mayerhoefer, Markus Raderer, Ulrich Jaeger, Philipp Staber, Barbara Kiesewetter, Daniela Senn, Ferdia A. Gallagher, Kevin Brindle, Edit Porpaczy, Michael Weber, Dominik Berzaczy, Ingrid Simonitsch-Klupp, Christian Sillaber, Cathrin Skrabs & Alexander Haug. (2018) Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment. European Journal of Nuclear Medicine and Molecular Imaging 45:6, pages 931-940.
Crossref
Emma Guttman-Yassky & James G Krueger. (2017) Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?. Current Opinion in Immunology 48, pages 68-73.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.